1. Home
  2. STXS vs CRBU Comparison

STXS vs CRBU Comparison

Compare STXS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

N/A

Current Price

$0.85

Market Cap

139.3M

Sector

Health Care

ML Signal

N/A

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

N/A

Current Price

$0.42

Market Cap

138.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STXS
CRBU
Founded
1990
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.3M
138.3M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
STXS
CRBU
Price
$0.85
$0.42
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$3.00
★ $5.75
AVG Volume (30 Days)
561.1K
★ 5.0M
Earning Date
11-10-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 16.67
3.64
EPS
★ N/A
N/A
Revenue
★ $29,346,617.00
N/A
Revenue This Year
$6.04
$145.34
Revenue Next Year
$33.01
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.91
$0.44
52 Week High
$2.93
$3.53

Technical Indicators

Market Signals
Indicator
STXS
CRBU
Relative Strength Index (RSI) 21.13 22.79
Support Level N/A N/A
Resistance Level $1.96 $0.58
Average True Range (ATR) 0.06 0.04
MACD -0.01 0.02
Stochastic Oscillator 13.76 5.57

Price Performance

Historical Comparison
STXS
CRBU

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: